BRPI0817272A2 - Derivados de benzimidazol e indol substituídos por oxadiazol e oxazol como inibidores de dgat1 - Google Patents

Derivados de benzimidazol e indol substituídos por oxadiazol e oxazol como inibidores de dgat1

Info

Publication number: BRPI0817272A2
Authority: BR; Brazil
Prior art keywords: oxadiazole; oxazole; indole derivatives; substituted benzimidazole; dgat1 inhibitors
Prior art date: 2007-09-28

Application number

BRPI0817272-2A

Other languages

English (en)

Inventor

Young-Shin Kwak

Gary Mark Coppola

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-28

Filing date

2008-09-26

Publication date

2015-06-16

2008-09-26 Application filed by Novartis Ag filed Critical Novartis Ag

2015-06-16 Publication of BRPI0817272A2 publication Critical patent/BRPI0817272A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

BRPI0817272-2A 2007-09-28 2008-09-26 Derivados de benzimidazol e indol substituídos por oxadiazol e oxazol como inibidores de dgat1 BRPI0817272A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97606407P	2007-09-28	2007-09-28
PCT/EP2008/062900 WO2009040410A1 (en)	2007-09-28	2008-09-26	Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors

Publications (1)

Publication Number	Publication Date
BRPI0817272A2 true BRPI0817272A2 (pt)	2015-06-16

Family

ID=39971086

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0817272-2A BRPI0817272A2 (pt)	2007-09-28	2008-09-26	Derivados de benzimidazol e indol substituídos por oxadiazol e oxazol como inibidores de dgat1

Country Status (27)

Country	Link
US (2)	US7879850B2 (pt)
EP (1)	EP2205595B1 (pt)
JP (1)	JP5675359B2 (pt)
KR (1)	KR101616133B1 (pt)
CN (1)	CN101932576B (pt)
AR (1)	AR066169A1 (pt)
AU (1)	AU2008303541B2 (pt)
BR (1)	BRPI0817272A2 (pt)
CA (1)	CA2701053C (pt)
CL (1)	CL2008002871A1 (pt)
CO (1)	CO6251263A2 (pt)
CR (1)	CR11261A (pt)
CU (1)	CU20100049A7 (pt)
EA (1)	EA019347B1 (pt)
EC (1)	ECSP10010051A (pt)
ES (1)	ES2525703T3 (pt)
IL (1)	IL203797A (pt)
MA (1)	MA31707B1 (pt)
MX (1)	MX2010003264A (pt)
MY (1)	MY151551A (pt)
NZ (1)	NZ583285A (pt)
PE (1)	PE20090774A1 (pt)
TN (1)	TN2010000096A1 (pt)
TW (1)	TWI429642B (pt)
UA (1)	UA99305C2 (pt)
WO (1)	WO2009040410A1 (pt)
ZA (1)	ZA201000829B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008523133A (ja)	2004-12-14	2008-07-03	アストラゼネカアクチボラグ	Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
US7749997B2 (en)	2005-12-22	2010-07-06	Astrazeneca Ab	Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
ATE492541T1 (de)	2006-05-30	2011-01-15	Astrazeneca Ab	Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
AR066169A1 (es) *	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) *	2008-03-10	2009-09-17	Novartis Ag	Method of increasing cellular phosphatidyl choline by dgat1 inhibition
AR076126A1 (es) *	2009-03-18	2011-05-18	Schering Corp	Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
RU2012132682A (ru)	2009-12-31	2014-02-10	Пирамал Энтерпрайзис Лимитед	Ингибиторы диацилглицерин ацилтрансферазы
WO2011123401A1 (en) *	2010-03-30	2011-10-06	Novartis Ag	Uses of dgat1 inhibitors
WO2012044567A2 (en) *	2010-09-30	2012-04-05	Merck Sharp & Dohme Corp.	Imidazole derivatives
WO2012064569A1 (en) *	2010-11-08	2012-05-18	Merck Sharp & Dohme Corp.	Imidazole derivatives
ES2683350T3 (es)	2011-07-08	2018-09-26	Novartis Ag	Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
WO2013074387A1 (en) *	2011-11-14	2013-05-23	Merck Sharp & Dohme Corp.	Imidazole derivatives
WO2013169648A1 (en)	2012-05-07	2013-11-14	Novartis Ag	Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
WO2014054053A1 (en)	2012-10-03	2014-04-10	Advinus Therapeutics Limited	Spirocyclic compounds, compositions and medicinal applications thereof
RS58539B1 (sr) *	2012-11-23	2019-04-30	Glaxosmithkline Llc	Nova jedinjenja kao inhibitori diacilglicerin aciltransferaze
WO2014081996A1 (en) *	2012-11-23	2014-05-30	Glaxosmithkline Llc	Novel compounds as diacylglycerol acyltransferase inhibitors
US9796729B2 (en)	2012-11-23	2017-10-24	Glaxosmithkline Llc	Compounds as diacylglycerol acyltransferase inhibitors
CN103087045B (zh) *	2013-01-11	2015-08-12	上海交通大学	一种苯并咪唑类杂环化合物、药物组合物及其用途
CN104610152A (zh) *	2015-02-13	2015-05-13	佛山市赛维斯医药科技有限公司	一类环丙基酰肼类gpr119激动剂、制备方法及其用途
CN104672144A (zh) *	2015-02-13	2015-06-03	佛山市赛维斯医药科技有限公司	一种环丙基酰肼和硝基苯类gpr119激动剂、制备方法及其用途
PE20210158A1 (es)	2018-03-16	2021-01-26	Anji Pharmaceuticals Inc	Composiciones y metodos para tratar el estrenimiento grave
CN113166204B (zh) *	2018-11-27	2025-01-28	诺华股份有限公司	作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
EP3887363A1 (en)	2018-11-27	2021-10-06	Novartis AG	Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder
UY38485A (es)	2018-11-27	2020-06-30	Novartis Ag	Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2023084449A1 (en)	2021-11-12	2023-05-19	Novartis Ag	Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
CN117466863A (zh) *	2022-07-20	2024-01-30	盛睿泽华医药科技（苏州）有限公司	含芳香族取代基的苯并咪唑化合物及其制备方法和用途

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0882718T3 (da)	1995-12-28	2005-12-12	Astellas Pharma Inc	Benzimidazolderivater
EP1377549A1 (en)	2001-03-12	2004-01-07	Millennium Pharmaceuticals, Inc.	Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
WO2003015773A2 (en)	2001-08-13	2003-02-27	Janssen Pharmaceutica N.V.	2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
WO2008011131A2 (en)	2006-07-21	2008-01-24	Takeda Pharmaceutical Company Limited	Amide compounds
NZ539952A (en)	2002-11-22	2008-05-30	Japan Tobacco Inc	Fused bicyclic nitrogen-containing heterocyclic compounds for treating diabetes, obesity and syndrome X
US7132456B2 (en)	2002-12-11	2006-11-07	Eli Lilly And Company	MCH receptor antagonists
EP1590336B1 (en)	2003-01-27	2010-12-01	Merck Sharp & Dohme Corp.	Substituted pyrazoles, compositions containing such compounds and methods of use
AR044152A1 (es)	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
JP3878625B2 (ja) *	2003-06-20	2007-02-07	松下電器産業株式会社	振幅調整回路、モータ駆動制御装置、振幅調整方法、及びモータ駆動制御方法
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005013907A2 (en) *	2003-08-07	2005-02-17	Japan Tobacco Inc.	Pyrrolo[1,2-b]pyridazine derivatives
WO2005035526A1 (en)	2003-10-09	2005-04-21	Argenta Discovery Ltd.	Bicyclic compounds and their therapeutic use
AU2005214319B2 (en)	2004-02-12	2009-02-19	Merck Sharp & Dohme Corp.	Amino heterocyclic modulators of chemokine receptor activity
WO2005108370A1 (ja) *	2004-04-16	2005-11-17	Ajinomoto Co., Inc.	ベンゼン化合物
WO2005121132A1 (ja) *	2004-06-11	2005-12-22	Shionogi & Co., Ltd.	抗ｈｃｖ作用を有する縮合ヘテロ環化合物
US20070249620A1 (en)	2004-07-02	2007-10-25	Hitoshi Kurata	Urea Derivative
ES2357015T3 (es)	2004-10-15	2011-04-15	Bayer Healthcare Llc	Preparación y uso de derivados bifenil-4-ilcarbonilaminoácido para el tratamiento de la obesidad.
US7932275B2 (en)	2004-10-29	2011-04-26	Merck, Sharp & Dohme Corp.	2-aminopyridine compounds useful as β-secretase inhibitors for the treatment of alzheimer's disease
JP2008523133A (ja)	2004-12-14	2008-07-03	アストラゼネカアクチボラグ	Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
WO2006082952A1 (ja)	2005-02-01	2006-08-10	Takeda Pharmaceutical Company Limited	アミド化合物
AU2006236155A1 (en)	2005-04-19	2006-10-26	Bayer Pharmaceuticals Corporation	Aryl alkyl acid derivatives for and use thereof
KR100910440B1 (ko)	2005-05-10	2009-08-04	에프. 호프만-라 로슈 아게	다이아실글리세롤 아실트랜스퍼레이즈 억제제
MX2007015759A (es)	2005-06-11	2008-02-21	Astrazeneca Ab	Derivados de oxadiazol como inhibidores de diacilglicerol aciltransferasa (dgat).
US20100016295A1 (en)	2005-07-29	2010-01-21	Bayer Healthcare Llc	Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of Obesity
RU2385865C2 (ru)	2005-08-15	2010-04-10	Айрм Ллк	Соединения и композиции в качестве миметиков тро
EP2298770A1 (en)	2005-11-03	2011-03-23	ChemBridge Corporation	Heterocyclic compounds as TrkA modulators
AU2006316560B2 (en)	2005-11-28	2011-06-16	Madrigal Pharmaceuticals, Inc.	Inhibitors of diacyglycerol acyltransferase (DGAT)
US7749997B2 (en)	2005-12-22	2010-07-06	Astrazeneca Ab	Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors
WO2007137103A2 (en)	2006-05-19	2007-11-29	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2007137107A2 (en)	2006-05-19	2007-11-29	Abbott Laboratories	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
ATE492541T1 (de)	2006-05-30	2011-01-15	Astrazeneca Ab	Substituierte 5-phenylamino-1,3,4-oxadiazol-2- ylcarbonylamino-4-phenoxycyclohexancarbonsäuren als inhibitoren von acetylcoenzym-a- diacylglycerolacyltransferase
US8003676B2 (en)	2006-05-30	2011-08-23	Astrazeneca Ab	1,3,4-oxadiazole derivatives as DGAT1 inhibitors
JP2009539816A (ja)	2006-06-06	2009-11-19	アストラゼネカアクチボラグ	化学化合物
CN101460492A (zh)	2006-06-08	2009-06-17	阿斯利康(瑞典)有限公司	苯并咪唑及其治疗糖尿病的用途
GB0611506D0 (en)	2006-06-10	2006-07-19	Astrazeneca Ab	Chemical compounds
GB0611507D0 (en)	2006-06-10	2006-07-19	Astrazeneca Ab	Chemical compounds
GB0611552D0 (en)	2006-06-12	2006-07-19	Astrazeneca Ab	Chemical compounds
WO2008011130A2 (en)	2006-07-21	2008-01-24	Takeda Pharmaceutical Company Limited	Amide compounds
ATE523497T1 (de)	2006-11-15	2011-09-15	High Point Pharmaceuticals Llc	Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
NZ597247A (en)	2006-11-29	2013-06-28	Abbott Lab	Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme
US20100093733A1 (en)	2007-02-15	2010-04-15	Prosidion Limited	Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en)	2007-04-20	2007-05-30	Astrazeneca Ab	Chemical compounds
KR20100017508A (ko)	2007-04-30	2010-02-16	아보트 러보러터리즈	디아실글리세롤 ｏ-아실트랜스퍼라제 타입 1 효소의 억제제
NZ580662A (en)	2007-04-30	2012-01-12	Abbott Lab	Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
US8115011B2 (en)	2007-05-22	2012-02-14	Madrigal Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
US8058299B2 (en)	2007-05-22	2011-11-15	Via Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
CN101835757B (zh)	2007-05-22	2014-03-05	玛德瑞哥制药公司	二酰甘油酰基转移酶抑制剂
US8153644B2 (en)	2007-05-22	2012-04-10	Madrigal Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
US8835437B2 (en)	2007-06-08	2014-09-16	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
AU2008258487B2 (en)	2007-06-08	2012-11-15	Janssen Pharmaceutica N.V.	Piperidine/piperazine derivatives
JO2972B1 (en)	2007-06-08	2016-03-15	جانسين فارماسوتيكا ان. في	Piperidine / piperazine derivatives
ES2483898T3 (es)	2007-06-08	2014-08-08	Janssen Pharmaceutica, N.V.	Derivados de piperidina/piperazina
WO2009011285A1 (ja)	2007-07-13	2009-01-22	Taisho Pharmaceutical Co., Ltd.	ヘテロアリールベンゼン化合物
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
MX2010001848A (es)	2007-08-17	2010-03-10	Astrazeneca Ab	Derivados de oxadiazol como inhibidores de diacilglicerolaciltrans ferasa (dgat).
US20090076275A1 (en)	2007-09-19	2009-03-19	David Robert Bolin	Diacylglycerol acyltransferase inhibitors
AR066169A1 (es) *	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009071483A1 (en)	2007-12-07	2009-06-11	Via Pharmaceuticals, Inc.	1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors
WO2009081195A1 (en)	2007-12-20	2009-07-02	Astrazeneca Ab	Carbamoyl compounds as dgat1 inhibitors 190
AU2009230127B2 (en)	2008-03-26	2011-12-22	Daiichi Sankyo Company, Limited	Novel tetrahydroisoquinoline derivative
JP5579170B2 (ja)	2008-06-05	2014-08-27	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｄｇａｔ阻害剤とｐｐａｒ作動薬を含有する薬剤組み合わせ物
PE20110105A1 (es) *	2008-07-15	2011-02-25	Novartis Ag	Derivados de heteroarilo como inhibidores de dgat1

2008
- 2008-09-25 AR ARP080104165A patent/AR066169A1/es not_active Application Discontinuation
- 2008-09-26 CN CN200880104322.3A patent/CN101932576B/zh not_active Expired - Fee Related
- 2008-09-26 MX MX2010003264A patent/MX2010003264A/es active IP Right Grant
- 2008-09-26 NZ NZ583285A patent/NZ583285A/en not_active IP Right Cessation
- 2008-09-26 WO PCT/EP2008/062900 patent/WO2009040410A1/en not_active Ceased
- 2008-09-26 EA EA201000428A patent/EA019347B1/ru not_active IP Right Cessation
- 2008-09-26 PE PE2008001688A patent/PE20090774A1/es not_active Application Discontinuation
- 2008-09-26 UA UAA201003529A patent/UA99305C2/ru unknown
- 2008-09-26 AU AU2008303541A patent/AU2008303541B2/en not_active Ceased
- 2008-09-26 TW TW097137382A patent/TWI429642B/zh not_active IP Right Cessation
- 2008-09-26 JP JP2010526300A patent/JP5675359B2/ja not_active Expired - Fee Related
- 2008-09-26 CA CA2701053A patent/CA2701053C/en not_active Expired - Fee Related
- 2008-09-26 KR KR1020107006598A patent/KR101616133B1/ko not_active Expired - Fee Related
- 2008-09-26 EP EP08804779.0A patent/EP2205595B1/en active Active
- 2008-09-26 MY MYPI20100653 patent/MY151551A/en unknown
- 2008-09-26 BR BRPI0817272-2A patent/BRPI0817272A2/pt not_active Application Discontinuation
- 2008-09-26 US US12/239,029 patent/US7879850B2/en not_active Expired - Fee Related
- 2008-09-26 CL CL2008002871A patent/CL2008002871A1/es unknown
- 2008-09-26 ES ES08804779.0T patent/ES2525703T3/es active Active
2010
- 2010-02-04 ZA ZA2010/00829A patent/ZA201000829B/en unknown
- 2010-02-08 IL IL203797A patent/IL203797A/en not_active IP Right Cessation
- 2010-02-10 CR CR11261A patent/CR11261A/es not_active Application Discontinuation
- 2010-02-25 TN TNP2010000096A patent/TN2010000096A1/fr unknown
- 2010-03-17 CU CU2010000049A patent/CU20100049A7/es not_active IP Right Cessation
- 2010-03-17 MA MA32702A patent/MA31707B1/fr unknown
- 2010-03-26 EC EC2010010051A patent/ECSP10010051A/es unknown
- 2010-04-19 CO CO10045481A patent/CO6251263A2/es active IP Right Grant
- 2010-12-09 US US12/964,170 patent/US8217065B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MA31707B1 (fr)	2010-09-01
IL203797A (en)	2014-01-30
PE20090774A1 (es)	2009-07-17
CO6251263A2 (es)	2011-02-21
CR11261A (es)	2010-04-26
JP2011501735A (ja)	2011-01-13
TWI429642B (zh)	2014-03-11
MX2010003264A (es)	2010-04-01
CN101932576A (zh)	2010-12-29
EP2205595B1 (en)	2014-09-10
AR066169A1 (es)	2009-07-29
US8217065B2 (en)	2012-07-10
CU20100049A7 (es)	2011-09-21
WO2009040410A1 (en)	2009-04-02
UA99305C2 (ru)	2012-08-10
EP2205595A1 (en)	2010-07-14
CU23901B1 (pt)	2013-06-28
KR101616133B1 (ko)	2016-04-27
ECSP10010051A (es)	2010-04-30
ZA201000829B (en)	2010-12-29
AU2008303541B2 (en)	2012-06-07
TW200914449A (en)	2009-04-01
CL2008002871A1 (es)	2009-05-15
AU2008303541A1 (en)	2009-04-02
TN2010000096A1 (en)	2011-09-26
ES2525703T3 (es)	2014-12-29
MY151551A (en)	2014-06-13
US20090186891A1 (en)	2009-07-23
NZ583285A (en)	2012-05-25
US20110077277A1 (en)	2011-03-31
KR20100071048A (ko)	2010-06-28
CA2701053A1 (en)	2009-04-02
EA019347B1 (ru)	2014-03-31
CN101932576B (zh)	2014-09-10
JP5675359B2 (ja)	2015-02-25
EA201000428A1 (ru)	2010-10-29
CA2701053C (en)	2016-08-23
US7879850B2 (en)	2011-02-01

Publication	Publication Date	Title
BRPI0817272A2 (pt)	2015-06-16	Derivados de benzimidazol e indol substituídos por oxadiazol e oxazol como inibidores de dgat1
LTPA2020528I1 (lt)	2020-09-25	Benzimidazolo dariniai
ES2643164T3 (es)	2017-11-21	Indol 7-sustituido como inhibidores de Mcl-1
BRPI1014582A2 (pt)	2016-04-26	benzimidazois, benzotiazois e benzoxazoles substituidos
BRPI0818457A2 (pt)	2015-04-14	Derivados de oxadiazol
BRPI0918846A2 (pt)	2019-09-24	inibidores de cinase heterocíclica
BRPI1013422A2 (pt)	2016-04-05	derivados de oxadiazol
CR10879A (es)	2009-08-05	Cyclized derivatives as eg-5 inhibitors
DK2389382T3 (da)	2013-07-08	Aminoheterocykliske forbindelser anvendt som pde9-inhibitorer
EP2346508A4 (en)	2012-04-18	HETEROCYCLIC KINASE HEMMER
ATE509927T1 (de)	2011-06-15	Indolderivate als s1p1-rezeptor-agonisten
DK2152712T3 (da)	2012-03-26	Aminoheterocykliske fobindelser
BRPI0911444A2 (pt)	2015-09-29	benzoimidazóis como inibidores de prolil hidroxilase
EP2264017A4 (en)	2011-07-27	Heterocyclic derivative and its use
BR112012010502A2 (pt)	2016-03-15	derivados de benzimidazol-imidazol
DE112009002169A8 (de)	2012-05-16	Energieversorgungsvorrichtung
EP2192838A4 (en)	2011-07-27	HETEROCYCLIC NEKROPTOSIS HEMMER
ATE526325T1 (de)	2011-10-15	Substituierte benzimidazole als kinaseinhibitoren
BRPI0811065A2 (pt)	2014-12-02	Indazóis 5-heteroaril substituídos como inibidores de quinase
ATE518840T1 (de)	2011-08-15	Benzimidazolonchymasehemmer
BRPI0820131A2 (pt)	2015-05-12	Derivados de oxadiazol ativos em esfingosina-1-fosfato (s1p)
BRPI0715324A2 (pt)	2015-06-23	Composto de indol
EP2349655A4 (en)	2013-09-25	ROCK DRILL AND AXIAL BEARING MODULE
BRPI0906705A2 (pt)	2015-06-30	Composto heterocíclicos
BRPI0821315A2 (pt)	2019-09-24	compostos benzimidazol

Legal Events

Date	Code	Title	Description
2017-10-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-05-28	B07E	Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2019-11-12	B11B	Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements